Products
Pre-made Remtolumab benchmark antibody ( Bispecific Dual Variable Domain IG, anti-IL17A/IL17;TNFA/TNF therapeutic antibody, Anti-CTLA-8/CTLA8;DIF/TNF-alpha/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-478
Pre-made Remtolumab benchmark antibody (Bispecific Dual Variable Domain IG, anti-IL17A/IL17;TNFA/TNF therapeutic antibody, Anti-CTLA-8/CTLA8;DIF/TNF-alpha/TNFSF2/TNLG1F Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Remtolumab (ABT 122) is a dual-variable domain immunoglobulin, targeting tumour necrosis factor (TNF) and interleukin-17 (IL-17), that was being developed by AbbVie, for the treatment of rheumatoid arthritis and psoriatic arthritis.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-478-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-478-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-478-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-478-xmg | ＞100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-made Remtolumab benchmark antibody (Bispecific Dual Variable Domain IG, anti-IL17A/IL17;TNFA/TNF therapeutic antibody, Anti-CTLA-8/CTLA8;DIF/TNF-alpha/TNFSF2/TNLG1F Antibody) |
| INN Name | Remtolumab |
| Target | IL17;TNF |
| Format | Bispecific Dual Variable Domain IG |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 4nyl:EF:AB:HL:CD/6cr1:HL;None |
| 99% SI Structure | 3wd5:HL;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Abbott Laboratories;Abbvie |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Psoriatic arthritis;Rheumatoid arthritis |
| Development Tech | Dual Variable Domain Immunoglobulin Technology |
